**Defining Hypertension by Blood Pressure 130/80 mm Hg Leads to an Impressive Burden of Hypertension in Young and Middle-Aged Black Adults: Follow-Up in the CARDIA Study**

Brent M. Egan, MD

Hypertension is a major contributor to a greater cardiovascular and renal disease burden among blacks than whites. The racial disparities are greatest in younger adults and decline with advancing age. The article in this issue of the *Journal of the American Heart Association (JAHA)* by Thomas et al, “Cumulative Incidence of Hypertension by 55 Years of Age in Blacks and Whites: the CARDIA Study,” highlights large racial disparities in incident hypertension between young black and white adults and has important implications for reducing disparities in prevalent hypertension and cardiovascular and renal complications in younger black adults.

This commentary will address 4 points related to the current report by Thomas et al:

1. High absolute risk of hypertension, defined by systolic blood pressure (BP) ≥ 130 mm Hg and/or diastolic BP ≥ 80 mm Hg or treatment for hypertension.
2. Relative and absolute risk of stage 1 hypertension (130–139/85–89 mm Hg) for clinical cardiovascular disease (CVD) in blacks.
3. Benefits of lifestyle intervention for prevention of hypertension and CVD.
4. Rationale for pharmacotherapy of stage 1 hypertension in blacks.

**High Absolute Risk of Hypertension in Blacks With Normal and High Normal BP**

In US adults, the prevalence of hypertension using the 2017 American College of Cardiology/American Heart Association Hypertension Guideline definition of systolic BP ≥ 130 mm Hg and/or diastolic BP ≥ 80 mm Hg is ≈ 46% versus 32% at ≥ 140/≥ 90 mm Hg. Among young adults in the CARDIA (Coronary Artery Risk Development in Young Adults) Study who had baseline BP < 130/< 80 mm Hg at ages 18 to 30 years, by age 55 years, ≈ 75% of black men and women were hypertensive in contrast to 54% of white men and 40% of white women (Figure). For the subset of black men and women who had baseline BP in the high normal range of 120 to 129/75 to 79 mm Hg at age 18 to 30 years, ≈ 60% were hypertensive by age 35 years and ≈ 87% were hypertensive by age 55 years. Moreover, black men and women with baseline BP in the 110 to 119/70 to 74 mm Hg range developed hypertension over time at a rate similar to white men and women with baseline BP 120 to 129/75 to 79 mm Hg (ie, a difference of ≈ 10/5 mm Hg, with ≈ 60% of both racial groups hypertensive by age 47 years).

From another perspective, the age at which 30% of each of the 4 race-sex groups was hypertensive occurred at 35 and 39 years among black men and women versus 44 and 53 years for white men and women, respectively (Figure). In fully adjusted models accounting for age, sex, body mass index, systolic BP, diastolic BP, cigarette smoking, parental history of hypertension, highest level of education, physical fitness, serum uric acid, alcohol consumption, and Dietary Approaches to Stop Hypertension eating plan concordance, blacks were 1.5 to 2.5 times more likely to develop hypertension than their white counterparts. Treating hypertension does not completely abolish excess hypertension-related risk. Thus, eliminating racial disparities in incident hypertension, which ultimately will lead to eliminating disparities in prevalent hypertension, is an important component of any credible plan to attain cardiovascular health equity in black and white Americans.

**Relative and Absolute Risk of Stage 1 Hypertension for Clinical CVD in Blacks**

In the ARIC (Atherosclerosis Risk in Communities) Study, high normal BP was defined as 130 to 139/85 to 89 mm Hg.
Compared with subjects with normal BP (<120/80 mm Hg), individuals with high normal BP had a hazards ratio for CVD of 2.33 (95% confidence interval, 1.85–2.92), adjusted for study center, age, sex, race, body mass index, smoking, low- and high-density lipoprotein cholesterol, education level, physical activity, cholesterol-lowering medications, diabetes mellitus, fibrinogen, von Willebrand factor, and white blood cell count.6 Among blacks, the multivariable adjusted HR was even higher at 3.29 (95% confidence interval, 1.68–6.45), with an absolute CVD event rate of ≈1% annually. This is the threshold atherosclerotic CVD event rate for antihypertensive pharmacotherapy in the American College of Cardiology/American Heart Association 2017 Hypertension Guideline among adults with stage 1 hypertension and no major clinical CVD events (ie, primary prevention).

A report from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study confirmed a greater risk for stroke among blacks than whites for each 10–mm Hg increase of systolic BP after adjusting for confounders. The greater risk of stroke among blacks than whites with prehypertension and hypertension was more evident at ages <65 years than ≥65 years.7

Comment on Masked Hypertension

Another study by the investigative team raises the possibility that masked hypertension, which occurs more often in blacks than whites, contributes to the greater risk for incident hypertension as well as cardiovascular events in blacks.8 In other words, virtually all studies showing greater risk for incident hypertension and cardiovascular events in blacks than whites, are related to incident hypertension and cardiovascular outcomes.

Benefits of Lifestyle Intervention for Preventing Hypertension and CVD

The authors documented that higher levels of physical activity in blacks are associated with a lower incidence of hypertension.9 They also reported a powerful effect of concordance with the American Heart Association’s Life’s Simple 7 (LS7; nutrition, physical activity, cigarette smoking, body mass index, BP, cholesterol, and glucose) and incident hypertension in blacks.10 Blacks concordant on 6 of 7 LS7 variables had a 90% lower incidence of hypertension than their counterparts with 0 to 1 LS7 variables. The Dietary Approaches to Stop Hypertension eating plan lowers BP more effectively in blacks than whites, which is partially explained by differences in angiotensinogen polymorphisms.11 Numerous other studies have also linked healthy LS7 to a lower incidence of diabetes mellitus, CVD, chronic kidney disease, dementia, and cancer.12 Given the extraordinarily high risk of hypertension by age 55 years in blacks as well as a substantial risk in whites, greater attention to effective and low-cost community-wide (highly scalable) interventions is urgently needed.

Rationale for Pharmacotherapy of Stage 1 Hypertension in Blacks Without Major Clinical CVD Events

Blacks have a much higher incidence of hypertension by age 55 years than whites, defined by systolic BP ≥130 mm Hg. Blacks also appear to have a greater incidence of clinical CVD in the BP range of 130 to 139/85 to 89 mm Hg than whites. The 2017 American College of Cardiology/American Heart Association Hypertension Guideline recommendation to begin antihypertensive pharmacotherapy for stage 1 hypertension when 10-year atherosclerotic CVD risk is ≥10% for primary prevention has a substantial evidence base and potentially may be more beneficial in blacks than whites.13 This author has expressed concern about the class I recommendation for antihypertensive pharmacotherapy as primary prevention in adults with stage 1 hypertension (BP, 130–139/80–89 mm Hg) given the paucity of data on the benefit of antihypertensive medications for primary prevention in this group.14 Yet, in 2010, we stated that concerned clinicians may elect to begin antihypertensive pharmacotherapy for stage 1 hypertension when 10-year atherosclerotic CVD risk is ≥10% for primary prevention when systolic BP is 130 to 139 mm Hg and absolute 10-year CVD risk is ≥10%.15 The concern is with the level of evidence and not the recommendation.
Clinical Implications

Blacks have a markedly higher incidence than whites of stage 1 hypertension by age 55 years. Moreover, the age at which 30% of previously nonhypertensive young adults become hypertensive is substantially lower in blacks than whites. In fact, 30% of black men developed stage 1 hypertension by age 35 years, a time of life in which primary health care is infrequently obtained. In contrast, 30% of white women developed hypertension by age 53 years, a time when the overwhelming majority of this group receives regular primary health care. Although stroke incidence has declined 80% in the past 60 years, the 4-fold greater risk of stroke in black men than white women persists. Reducing the persistent relative disparity will almost certainly require effective attention to the wide disparity in age of onset and the prevalence of hypertension between black men and white women, especially at ages <55 years.

The authors have other reports indicating that physical activity and greater concordance with LS7, and especially physical activity, good nutrition, and maintenance of normal body weight, are highly effective in reducing incident hypertension in blacks. Cost-effective and highly scalable approaches to healthy lifestyles patterns are urgently needed, especially in younger blacks. Because many blacks <55 years of age have 10-year CVD risk >10% or higher, effective pharmacotherapy should attenuate progression to more severe hypertension and potentially reduce cardiovascular events. Novel approaches to hypertension prevention, detection, treatment, and control may be required to improve health equity, given large racial differences in the age of onset, prevalence, and severity of hypertension.

Disclosures

None.

References

1. Howard G, Peace F, Howard VJ. The contributions of selected diseases to disparities in death rates for racial/ethnic minorities in US, 1999–2010. Prev Chronic Dis. 2014;11:E129.
2. Benjamin EJ, Virani SS, Callaway CW, Chang AR, Cheng S, Chuve SE, Cushman M, Delling FH, Deo R, de Ferranti SD, Ferguson JF, Formage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchie MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
3. Thomas SJ, Booth JN III, Dai C, Li X, Allen N, Calhoun D, Carson AP, Gidding S, Lewis CE, Shikany JM, Shimbo D, Sidney S, Muntner P. Cumulative incidence of hypertension by 55 years of age in blacks and whites: the CARDIA Study. J Am Heart Assoc. 2018;7:e007988. DOI: 10.1161/JAHA.117.002155.
4. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK. Potential U.S. population impact of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. J Am Coll Cardiol. 2018;71:109–118.
5. Lieb W, Enserro DM, Sullivan LM, Vasan RS. Residual cardiovascular risk in individuals on blood pressure-lowering treatment. J Am Heart Assoc. 2015;4: e002155. DOI: 10.1161/JAHA.115.002155.
6. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with elevated risk of cardiovascular disease. Am J Med. 2006;119:133–141.
7. Howard G, Lackland DT, Klodorfer DO, Kissa BM, Mosley TH, Safford MM, Cushman M, Glasser SP, Howard VJ. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med. 2013;173:46–51.
8. Booth JN, Diaz KM, Seals SR, Sims M, Ravenell J, Muntner P, Shimbo D. Masked hypertension and cardiovascular disease events in a prospective cohort of blacks. Hypertension. 2016;68:501–510.
9. Diaz KM, Booth JN III, Seals SR, Abdalla M, Dubbert PM, Sims M, Ladapo JA, Redmond N, Muntner P, Shimbo D. Physical activity and incident hypertension in African Americans: the Jackson Heart Study. Hypertension. 2017;68:421–427.
10. Booth JN III, Abdalla M, Tanner RM, Diaz KM, Bromfield SG, Tajeu GS, Correa A, Sims M, Ogedegbe G, Bress AP, Spruijl TM, Shimbo D, Muntner P. Cardiovascular health and incident hypertension in blacks: JHS (The Jackson Heart Study). Hypertension. 2017;70:285–292.
11. Svetkey LP, Harris EL, Martin E, Vollmer WM, Meltsen GT, Ricchiuti V, Williams G, Appel LJ, Bray GA, Moore TJ, Winn MP, Conlin PR. Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system. Am J Hypertens. 2011;24: e209–e217.
12. Egan BM. Is Life’s Simple 7 a practical paradigm for promoting healthy blood pressure, preventing cardiovascular disease and improving total health? J Am Soc Hypertens. 2018;12:324–326.
13. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Oviabiele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/ABC/ACP/AGS/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71: e13–e115.
14. Egan BM, Li J, Wagner CS. Systolic blood pressure intervention trial (SPRINT) and target systolic blood pressure in future hypertension guidelines. Hypertension. 2016;68:318–323.
15. Egan BM, Lackland DT, Jones DW. Pre-hypertension: an opportunity for a new public health paradigm. Cardiol Clin. 2010;28:561–569.
16. Victor RG, Lough K, Li N, Byler C, Muhammad E, Handler J, Bittler J, Rashid M, Hsu B, Fox-Drew D, Moy N, Reid AE, Elshoff RM. A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med. 2018;378:1291–1301.

Key Words: Editorsials • definition • hypertension • incidence • prevention • racial differences